Avacta opens first US clinical investigator sites
6th Apr 2023 10:09
(Sharecast News) - Life sciences company Avacta has opened its first two clinical investigator sites in the US for a Phase 1 clinical study on its AVA6000 candidate.
Read moreAvacta doses first patient in higher-dose oncology cohort
5th Apr 2023 12:51
(Sharecast News) - Life sciences company Avacta Group announced that it had dosed the first patient in the fifth cohort of the first-in-human phase one trial of its innovative oncology drug 'AVA6000' on Wednesday.
Read moreAvacta to present tumour medicine data at cancer research meeting
27th Mar 2023 13:44
(Sharecast News) - Life science company Avacta Group announced on Monday that it will present a poster on its novel 'preCISION' medicine, 'AVA3996', at the American Association for Cancer Research (AACR) 2023 annual meeting in Florida on 16 April.
Read moreAvacta has 'no relationship' with failed tech-focussed bank
13th Mar 2023 10:08
(Sharecast News) - Life science company Avacta reassured the market on Monday, following the collapse of technology and science-focussed Silicon Valley Bank last week.
Read moreAvacta reports positive progress in chemotherapy trial
17th Jan 2023 17:16
(Sharecast News) - Oncology drug and diagnostics developer Avacta Group said in an update on Tuesday that 'AVA6000' was continuing to show a "very favourable" safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase-one clinical trial.
Read moreAvacta buying Launch Diagnostics for initial £24m
18th Oct 2022 11:12
(Sharecast News) - Clinical-stage oncology drug company Avacta has conditionally agreed to acquire Launch Diagnostics, it announced on Tuesday, for an upfront cash consideration of £24m on a debt-free, cash-free basis.
Read moreAvacta losses narrow as it progresses clinical programmes
29th Sep 2022 11:56
(Sharecast News) - Clinical-stage oncology drug developer Avacta reported first-half revenue of £5.5m on Thursday, up from £1.5m year-on-year and from £2.9m for the full 2021 period.
Read moreAvacta's soft tissue sarcoma treatment gets FDA orphan drug designation
5th Sep 2022 07:16
(Sharecast News) - Biotechnology company Avacta Group said on Monday that its soft tissue sarcoma treatment has been granted orphan drug designation by the US Food and Drug Administration.
Read moreAvacta joint venture completes fresh funding round
21st Jul 2022 15:29
(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Thursday that AffyXell, its joint venture with Daewoong Pharmaceuticals, has completed a funding round to advance its lead mesenchymal stem cell (MSC) programme towards the clinic, and to develop its wider preclinical pipeline of cell therapies.
Read moreAvacta triggers milestone in Daewoong joint venture
13th Apr 2022 13:57
(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Wednesday that a milestone equity payment has been triggered, resulting in an increase in its shareholding in AffyXell Therapeutics.
Read moreAvacta joint venture enters new immune model collaboration
8th Apr 2022 16:17
(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Friday that AffyXell Therapeutics - its joint venture with Daewoong Pharmaceutical - has entered into a collaboration agreement with Chinese biological drugs developer Biocytogen and the Korea Non-Clinical Technology Solution Center (KNTSC).
Read moreAvacta offloads animal health unit in £2.3m deal
16th Mar 2022 13:02
(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that Vimian Group has acquired its veterinary division, Avacta Animal Health, for consideration of up to £2.3m.
Read moreAvacta moves to next dose in first-in-human chemotherapy trial
3rd Feb 2022 12:31
(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Thursday that the first-in-human phase 1 trial of 'AVA6000' pro-doxorubicin would advance to the next dose cohort, following a positive review of the safety data from the dosing of the first cohort.
Read moreAvacta Group selects second pro-drug candidate
18th Jan 2022 14:36
(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Tuesday that the next 'preCISION' drug candidate, 'AVA3996', had been selected for preclinical development, with a view to a first-in-human phase one clinical trial from the second half of 2023.
Read moreShares plummet as Avacta pauses sale of lateral flow tests
10th Jan 2022 11:05
(Sharecast News) - Avacta Group has suspended sales of its antigen lateral flow tests, causing the AIM-listed firm's share price to plummet.
Read more